Repetitive Transcranial Magnetic Stimulation Treatment for Depressive Disorders

A Practical Guide



Repetitive Transcranial Magnetic Stimulation Treatment for Depressive Disorders

Paul B. Fitzgerald • Z. Jeff Daskalakis

Repetitive Transcranial Magnetic Stimulation Treatment for Depressive Disorders

A Practical Guide



Paul B. Fitzgerald Professor of Psychiatry Monash Alfred Psychiatry Research Centre Monash University Central Clinical School and The Alfred Melbourne Victoria Australia Z. Jeff Daskalakis Centre for Addiction and Mental Health (CAMH) University of Toronto Toronto Ontario Canada

ISBN 978-3-642-36466-2 ISBN 978-3-642-36467-9 (eBook) DOI 10.1007/978-3-642-36467-9 Springer Heidelberg New York Dordrecht London

Library of Congress Control Number: 2013936440

© Springer-Verlag Berlin Heidelberg 2013

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Preface

Depression is widely recognised as a common and significant problem that has a major impact on patients, their families, the health-care system and society in general. It is also widely recognised that the treatments available to date for depression have been insufficient to meet the needs of a considerable percentage of patients with this problem.

In this context, repetitive transcranial magnetic stimulation (rTMS) has been developed as a further treatment option. Considerable research efforts, undertaken by academic psychiatrists around the world for over 15 years, have clearly established the therapeutic efficacy of this treatment. Although considerable questions still need to be addressed in regard to the mechanism of action of rTMS and how best it should be applied, it clearly is able to substantially relieve depression for many patients who undergo this therapy.

In recent years, rTMS has progressively been approved for use in the treatment of depression in a substantial number of countries, and its use in clinical practice is now dramatically escalating. Clinicians throughout Europe, the USA, Canada and a number of other countries are increasingly utilising rTMS treatment in clinical practice across a variety of settings. However, only limited resources are currently available to support the widespread clinical utilisation of rTMS. There is a large and substantive academic literature exploring the use of this treatment, but this is not necessarily accessible in a timely manner to busy clinicians wishing to offer rTMS, or who, when using this treatment, are faced with new clinical problems.

This book is designed to address this gap. We aim to provide an accessible guide for clinicians in the use of rTMS treatment in clinical practice. The book aims to both summarise the scientific literature supporting the questions addressed, but also to provide succinct, accessible and clinically relevant information. The initial chapters provide background to aid the reader in understanding the science underpinning the use of rTMS treatment. We then consider in some depth specific aspects to do with the application of rTMS treatment of depression, including the safety of treatment and its potential side effects. We then describe both the evidence base for its use in the treatment of depression and the clinical considerations relevant to the selection of treatment parameters and identification of appropriate patients. In the final chapters, we address practical issues in treatment provision in the application of rTMS in other disorders. This book is primarily written for clinicians who are considering providing rTMS treatment in clinical practice, or who are already doing so. However, we hope it will also provide a useful primer for researchers considering undertaking academic study in this area. As is illustrated in the pages of this book, considerable questions still need to be addressed as regards the optimisation of rTMS treatment in clinical practice. We are hopeful that academic exploration of this therapy will continue to address this important area.

We would like to thank Sally Herring for her invaluable assistance with editing and putting together this book. Paul Fitzgerald would like to acknowledge the support of an NHMRC Practitioner Fellowship and Jeff Daskalakis would like to thank CIHR for their Clinician Scientist Award. We would both very much like to thank our families for their support and encouragement: Elle, Jake, Sian, Stella, Taso and Elly!

Melbourne, VIC, Australia Toronto, ON, Canada Paul B. Fitzgerald Z. Jeff Daskalakis

Contents

1	An Introduction to the Basic Principles of TMS and rTMS			1	
	1.1	Introd	uction	1	
	1.2	Overv	iew of TMS Technology	1	
	1.3	Overv	iew of Repetitive TMS (rTMS) Technology	3	
	1.4	Sham	Stimulation	4	
	1.5	Noise		5	
	Refe	rences .		5	
2	The History of TMS and rTMS Treatment of Depression				
	2.1		uction	7	
	2.2	Early 2	Attempts to Develop TMS-Like Approaches	8	
	2.3	The D	evelopment of Modern TMS	10	
	Refe	rences .		11	
3	The Mechanism of Action of rTMS			13	
	3.1	Introd	uction	13	
	3.2 Effects of rTMS Assessed in the Motor Cortex.		s of rTMS Assessed in the Motor Cortex	13	
		3.2.1	Effects on Motor Cortical Excitability	14	
		3.2.2	Effects on Motor Cortical Inhibition and Facilitation	15	
		3.2.3	Effects of rTMS on Motor Cortical Plasticity	18	
	3.3	Effects	s of rTMS Assessed with EEG	19	
	3.4	Neuro	imaging Studies of the Effect of rTMS	20	
		3.4.1	Imaging of rTMS Effects	20	
		3.4.2	Imaging of rTMS Effects in Depression	21	
		3.4.3	Studying Brain Effects of rTMS		
			with Near-Infrared Spectroscopy	22	
	3.5	Studyi	ing Brain Effects of rTMS with Electroencephalography	22	
	3.6	Effects	s of rTMS on BDNF	23	
	Refe	rences .		24	
4	Acut	te rTMS	S Treatment for Depression	29	
	4.1	rTMS	in Depression: High-Frequency Stimulation	29	
		4.1.1	Meta-Analysis	36	
		4.1.2	rTMS Versus ECT	37	
		4.1.3	Summary	37	

	4.2	Low-Frequency Right-Sided rTMS	38
	4.3	Bilateral rTMS	39
	4.4	Other Approaches	39
		4.4.1 Priming	39
		4.4.2 Theta Burst Stimulation (TBS)	40
	4.5	Other rTMS Methodological Issues	40
		4.5.1 Treatment Targeting	40
		4.5.2 Altered Coil Design and Profile of Stimulation	43
	4.6	Issues with the Conduct of Clinical Trials of rTMS	43
	Refe	rences	44
5	Clin	ical Indications and Patient Selection	49
5	5.1	Stage of Illness and Treatment Resistance	49
	5.1	5.1.1 Clinical Recommendations	51
	5.2	Illness Type: Unipolar and Bipolar Depression.	51
	5.2	5.2.1 Clinical Recommendations	52
	5.3	Elderly Patients with Depression.	52
	5.5	5.3.1 Clinical Recommendations	53
	5.4	Adolescent Depression	53
	5.7	5.4.1 Clinical Recommendations	54
	5.5	Pregnant or Breastfeeding Patients	54
	0.0	5.5.1 Clinical Recommendations	55
	5.6	Concurrent Illness: Neurological Disease	55
	5.0	5.6.1 Clinical Recommendations	56
	5.7	Other Factors	56
		rences	57
6	6.1	tical Issues in Treatment Provision	61 61
	6.1 6.2	Introduction	61
	0.2	Dosing and Motor Threshold. 6.2.1 Clinical Recommendations	66
	6.3		67
	0.3	Selection of Treatment Type and Parameters	07
			67
		rTMS	67 68
		6.3.2 Use of Right-Sided Low-Frequency rTMS6.3.3 Sequential Bilateral rTMS	
	6.4	1	68
	0.4	Treatment Scheduling and Duration	69 71
	65	6.4.1 Clinical Recommendations	71
	6.5	Concurrent Treatments	71
	((6.5.1 Clinical Recommendations	72
	6.6	Coil Positioning and Location	75
	Def	6.6.1 Clinical Recommendations	76
	Kefe	rences	78
7	rTM	S-Associated Adverse Events, Safety and Monitoring	81
	7.1	Introduction	81
	7.2	Contraindications	81

	7.3	Adverse Events	82
		7.3.1 Syncope	82
		7.3.2 Seizure Induction	83
	7.4	Other Potential Safety Concerns	85
		7.4.1 Impairment of Cognition	85
		7.4.2 Hearing Impairment	86
		7.4.3 Potential Histotoxicity or Other Brain Changes	86
		7.4.4 Pregnancy: Breastfeeding	87
		7.4.5 Children and Adolescents.	87
	7.5	Safety of Operators	88
	Refe	rences	88
8	Side	Effects of rTMS Treatment	91
	8.1	Introduction	91
	8.2	Site or Regional Pain	91
	8.3	Headache	92
	8.4	Psychiatric Complications	92
	8.5	Seizure Risk and Other Considerations	93
	Refe	rences	94
9	Mair	ntenance and Continuation Treatment	95
1	9.1	Introduction	95
	9.2	Rates of Relapse Following rTMS Treatment	95
	9.3	Approaches to Minimise Relapse	96
		9.3.1 Medication Treatment	97
		9.3.2 Psychotherapy	97
	9.4	Maintenance rTMS Treatment.	98
	9.5	Repeated rTMS Treatment	99
	9.6	Summary	100
	Refe	rences	100
10	The	Use of rTMS in Other Psychiatric Disorders	103
	10.1	Introduction	103
	10.2	Mania	103
		10.2.1 Summary	104
	10.3	Anxiety Disorders	104
		10.3.1 Obsessive-Compulsive Disorder (OCD)	104
		10.3.2 Post-traumatic Stress Disorder	105
		10.3.3 Panic Disorder and Generalised Anxiety Disorder	105
	10.4	Schizophrenia	106
		10.4.1 Prefrontal Stimulation in Schizophrenia	107
		10.4.2 Temporoparietal Cortex rTMS	
		and Auditory Hallucinations	108
		10.4.3 Summary	110
	10.5	Pain	110
		10.5.1 Summary	111
	Refe	rences	112

11	Equipment and rTMS Programme Set-Up		
	11.1	TMS Equipment	117
		11.1.1 MagVenture	118
		11.1.2 Magstim	118
		11.1.3 Neuronetics	119
		11.1.4 Other	119
	11.2	Treatment Programme Establishment	119
	11.3	Patient Information and Consent	120
Ind	ex		123

An Introduction to the Basic Principles of TMS and rTMS

1.1 Introduction

Transcranial magnetic stimulation (TMS) is a unique experimental tool that allows researchers to non-invasively stimulate and study the cortex in healthy and diseased states [1] (Fig. 1.1). It has been used both as an investigational tool to measure a variety of cortical phenomena including cortical inhibition and plasticity [2, 3], as a probe to explore cognitive mechanisms [4] and as a treatment tool in illnesses such as depression and schizophrenia [5, 6]. This chapter will review the physical principles of TMS and repetitive transcranial magnetic stimulation (rTMS) and the neuronal structures activated by the techniques.

1.2 Overview of TMS Technology

In 1831 Michael Faraday demonstrated that a current was induced in a secondary circuit when it was brought in close proximity to the primary circuit in which a time-varying current was flowing. Here, a changing electrical field produces a changing magnetic field that, consistent with Faraday's law, causes current to flow in a nearby conducting material. With TMS, electrical charge is stored in capacitors. Periodic discharge of this stored energy from the capacitors and through a conducting coil produces a time-varying electrical field. This electrical field produces a transient magnetic field that will cause current to flow in an appropriately located secondary conducting material, such as neurons. If this current induced in the brain is of sufficient strength, it will produce depolarisation of the conducting neural tissue located just under the coil.

As described, electrical fields that are applied to neurons can excite these cells. The electrical field will produce a current in the intracellular and extracellular space. This causes cell membranes to become depolarised. An action potential is initiated when this depolarisation is of significant magnitude. Electrical fields experience resistance because of scalp and skull and other intermediary tissue. Magnetic fields,




Fig. 1.1 A figure-of-8 Magstim coil held over the head in a custom-built stand. Electromyography (EMG) electrodes are placed to record muscle activity induced by stimulation of the motor cortex

by contrast, experience absolutely no resistance from the above-mentioned structures. The magnetic field strength, however, is significantly reduced in relationship to the distance between the stimulation target and the magnetic source. The circuit involved in TMS includes a capacitor, a thyristor switch and a coil. Charge and discharge of the capacitor are coordinated by the thyristor switch which acts as a gate for conduction of the electrical field through the coil. The field that is subsequently produced is either monophasic or biphasic. This difference depends on the properties of the circuit that is used.

Commercially available stimulators produce two pulse types: a biphasic pulse or a monophasic pulse. A biphasic pulse is sinusoidal and is generally of shorter duration than a monophasic pulse, which involves a rapid rise from zero, followed by a slow decay back to zero. In commercially available stimulators, several types of coils are typically used. These include circular and figure-of-eight-shaped coils. In general, figure-of-eight-shaped coils produce a stronger more focused magnetic field with better spatial resolution of activation compared to circular coils [7]. In contrast, circular coils tend to produce larger and deeper fields. This may be preferred when the neuroanatomic target is not precise. Iron-core coils are advantageous in that they tend to require less power to produce strong magnetic fields and, as a corollary, generate less heat [8]. By contrast, more traditional round or figureof-eight copper coils generate significant heat that increases as more pulses are delivered. Two methods are used to dissipate this heat. Air can be used to effectively dissipate heat and many commercially available stimulators are indeed air-cooled. One drawback to air cooling is the loud noise of the air compressor. Liquid cooling can also be used. In this method the liquid helps dissipate the heat by surrounding the coil, allowing for rapid heat exchange from the copper wiring to the liquid which is contiguous but not in direct contact with the coil. The H-coil is a much newer type of coil with multiple coil windings developed to generate greater depth of penetration. For example, whilst conventional figure-of-eight coils lose 50 % of their magnetic field strength when the target is more than 2 cm from the stimulator, the H-coil is able to generate sufficient field strength at 6 cm [9]. This may be advantageous given the role of deeper cortical structures (e.g. the dorsal anterior cingulate and subgenual cingulate) in the pathophysiology of depression.

By and large, in small figure-of-eight-shaped coils, neurons are activated in a cortical area of approximately 2–3 cm² and to a depth of approximately 2 cm [10]. In most studies, figure-of-eight coils are held over the cortex flat and at about 45° from the midline position, perpendicular to the central sulcus. This induces a current from posterior to anterior direction, perpendicular to descending pyramidal neurons and parallel to interneurons, which modulate pyramidal cell firing [11]. It is the orientation between the coil and underlying neural tissue that allows researchers to selectively activate different groups of neurons providing useful information regarding neuronal inhibition, excitation and connectivity.

1.3 Overview of Repetitive TMS (rTMS) Technology

Repetitive transcranial magnetic stimulation (rTMS) involves stimulation of the cortex by a train of magnetic pulses at frequencies between 1 and 50 Hz, in contrast to single-pulse TMS in which the frequency of stimulation is <1 Hz [12]. Higher frequencies can be achieved because the bipolar stimulus, as opposed to a unipolar stimulus, is shorter and requires less energy to produce neuronal excitability. Thus, capacitors can charge and discharge rapidly, thereby achieving high stimulation rates. It is the ability to achieve such high stimulation rates that has made rTMS a valuable tool in investigation and treatment of many neuropsychiatric disorders.

Repetitive TMS can either activate or inhibit cortical activity, depending on stimulation frequency [13]. Low-frequency (~1 Hz) stimulation for a period of approximately 15 min induces a transient inhibition, or a decrease in activity, of the cortex [14]. The mechanisms behind such inhibition is unclear, although there are similarities to longterm depression, a cellular experimental phenomena where repeated low-frequency stimulation reduces activity in individual synapses [14]. In contrast, stimulation at frequencies above 1 Hz has been shown to induce increased cortical activation [15]. The mechanisms by which such activation occurs are also unclear, although some authors suggest that it may be due to a transient increase in the efficacy of excitatory synapses [16]. It has also been argued that the orientation between the coil and underlying neural tissue that allows researchers to selectively activate different groups of neurons may be key to understanding the principles mediating its therapeutic efficacy. That is, by virtue of the fact that TMS activates neurons transsynaptically [17] (i.e. activation of interneurons), neuronal stimulation can selectively activate or inhibit the cortex.